RAPTOR up-regulation contributes to resistance of renal cancer cells to PI3K-mTOR inhibition
Open Access
- 1 February 2018
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (2) , e0191890
Abstract
The outlook for patients with advanced renal cell cancer (RCC) has been improved by targeted agents including inhibitors of the PI3 kinase (PI3K)-AKT-mTOR axis, although treatment resistance is a major problem. Here, we aimed to understand how RCC cells acquire resistance to PI3K-mTOR inhibition. We used the RCC4 cell line to generate a model of in vitro resistance by continuous culture in PI3K-mTOR kinase inhibitor NVP-BEZ235 (BEZ235, Dactolisib). Resistant cells were cross-resistant to mTOR inhibitor AZD2014. Sensitivity was regained after 4 months drug withdrawal, and resistance was partially suppressed by HDAC inhibition, supporting an epigenetic mechanism. BEZ235-resistant cells up-regulated and/or activated numerous proteins including MET, ABL, Notch, IGF-1R, INSR and MEK/ERK. However, resistance was not reversed by inhibiting or depleting these pathways, suggesting that many induced changes were passengers not drivers of resistance. BEZ235 blocked phosphorylation of mTOR targets S6 and 4E-BP1 in parental cells, but 4E-BP1 remained phosphorylated in resistant cells, suggesting BEZ235-refractory mTORC1 activity. Consistent with this, resistant cells over-expressed mTORC1 component RAPTOR at the mRNA and protein level. Furthermore, BEZ235 resistance was suppressed by RAPTOR depletion, or allosteric mTORC1 inhibitor rapamycin. These data reveal that RAPTOR up-regulation contributes to PI3K-mTOR inhibitor resistance, and suggest that RAPTOR expression should be included in the pharmacodynamic assessment of mTOR kinase inhibitor trials.Keywords
Funding Information
- Cancer Research UK (C602/A6292)
- Oxford University Clinical Academic Graduate School
- Cancer Research UK Oxford Cancer Research Centre (C5255/A20758)
- National Institute for Health Research
This publication has 81 references indexed in Scilit:
- mTOR Signaling in Growth Control and DiseaseCell, 2012
- Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumorsAnnals of Oncology, 2012
- Type 1 Insulin-like Growth Factor Receptor Translocates to the Nucleus of Human Tumor CellsCancer Research, 2010
- The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell CarcinomaClinical Cancer Research, 2010
- Structure of the Human mTOR Complex I and Its Implications for Rapamycin InhibitionMolecular Cell, 2010
- mTORC1-Mediated Cell Proliferation, But Not Cell Growth, Controlled by the 4E-BPsScience, 2010
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell SubpopulationsCell, 2010
- The TSC-mTOR Pathway Mediates Translational Activation of TOP mRNAs by Insulin Largely in a Raptor- or Rictor-Independent MannerMolecular and Cellular Biology, 2009
- Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translationProceedings of the National Academy of Sciences, 2008
- Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR ComplexScience, 2005